Unknown

Dataset Information

Long term side effects of adjuvant chemotherapy in patients with early breast cancer.


ABSTRACT: Adjuvant systemic therapy along with screening has been key to the observed improvements in disease-free and overall survival (DFS/OS) in breast cancer. Improvements in overall survival already take into account therapy related toxicities that can result in death. However, this measure alone does not adequately capture the impact on health-related quality of life. Therefore, it is important to examine the prevalence, frequency and short/long-term impact of therapy-related toxicities, identify patients who might be at greatest risk. Ultimately decisions regarding expected therapy benefits (relative and absolute percentage improvements in DFS/OS) must be made against a background of known potential harms. For many patients with early breast cancer (EBC), their risk of recurrence is not zero

SUBMITTER: Tao JJ 

PROVIDER: S-EPMC4743500 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature